Cyprotex PLC Launch of New ADME Guide
October 15 2015 - 2:00AM
RNS Non-Regulatory
TIDMCRX
Cyprotex PLC
15 October 2015
Cyprotex PLC
("Cyprotex" or "the Company")
Launch of New ADME Guide
Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience
Contract Research Organisation, today announce the launch of their
new ADME guide titled 'Everything you need to know about ADME'.
ADME is an acronym for absorption, distribution, metabolism and
excretion, which are the processes occurring to a pharmaceutical
drug following dosing. Knowledge of these processes assist us in
understanding drug concentrations in the blood and tissues within
the body, which in turn influences efficacy, toxicity and potential
drug-drug interactions.
Our original ADME guide was launched back in 2006 and since this
time, Cyprotex have distributed thousands of copies to our fellow
scientists in the industry. Because of developments in the industry
over the past decade, the new guide, which is the 2(nd) edition, is
very different to the original version, and contains largely new
material. The new guide complements our existing 'Mechanisms of
Drug-Induced Toxicity' guide and our 'DDI Regulatory Guidance'
handbook.
Anthony Baxter PhD, Chief Executive Officer of Cyprotex,
comments on the launch of the new ADME guide, 'We have been
offering ADME services since the inception of the company in 1999.
Through our corporate responsibility policy, we aim to share our
experience and knowledge in the field for the benefit of our
customers and wider scientific community. Our guides have proved
extremely popular and provide a valuable resource for scientists in
a range of disciplines who want to have an up-to-date overview of
the current testing methods and how the data are interpreted in
both a drug discovery and development setting .'
To request a copy of our new 'Everything you need to know about
ADME' guide, please visit http://www.cyprotex.com/guides
For further information:
Cyprotex PLC Tel: +44 (0) 1625
505 100
Dr Anthony Baxter, Chief Executive ir@cyprotex.com
Officer www.cyprotex.com
John Dootson, Chief Financial
Officer
Mark Warburton, Chief Operating
Officer and Legal Counsel
N+1 Singer (Nomad and broker to Tel: +44 (0)20 7496
Cyprotex) 3000
Shaun Dobson shaun.dobson@n1singer.com
Jen Boorer jennifer.boorer@n1singer.com
www.n1singer.com
Notes to Editors
About Cyprotex PLC
Cyprotex is listed on the AIM market of the London Stock
Exchange (CRX). It has sites at Macclesfield and Alderley Park,
both of which are near Manchester in the UK, and at Watertown, MA
and Kalamazoo, MI in the US. The Company was established in 1999
and works with more than 1200 partners within the pharmaceutical
and biotech industry, cosmetics and personal care industry and the
chemical industry. Cyprotex acquired Apredica and the assets of
Cellumen Inc. in August 2010 and the combined business provides
support for a wide range of experimental and computational ADME-Tox
and PK services. The acquisition of the assets and business of
CeeTox in January 2014 has enabled Cyprotex to expand its range of
services to target the personal care, cosmetics and chemical
industries.
In 2015, Cyprotex launched its new bioscience division to expand
its capabilities into phenotypic and target based screening. The
Company's core capabilities include high quality in vitro ADME
screening services, mechanistic toxicology and high content
toxicology screening services, including our proprietary
CellCiphr(R) toxicity prediction technology, bioscience services,
predictive modelling using PBPK, including Cloe(R) PK for in vivo
PK prediction, and a range of skin, ocular and endocrine disruption
services. For more information, see www.cyprotex.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRABXBDGBSBBGUS
(END) Dow Jones Newswires
October 15, 2015 02:00 ET (06:00 GMT)
Cyprotex (LSE:CRX)
Historical Stock Chart
From Apr 2024 to May 2024
Cyprotex (LSE:CRX)
Historical Stock Chart
From May 2023 to May 2024